|
Audience: This activity is intended for healthcare professionals
practicing in managed care environments.
This activity is Sponsored by C2N
Diagnostics
Description:
Approximately 16 million Americans are living with mild cognitive
impairment and dementia and warrant a diagnostic evaluation to
determine the cause of their cognitive decline. Accurate and timely
detection of AD pathology in affected patients continues to be a
significant hurdle to delivering optimal care for patients with
signs and symptoms of cognitive decline. There is an urgent unmet
need for safe, lower cost, less resource-intensive, easily
accessible, and broadly available tests that identify the presence
or absence of brain amyloid plaques, a pathological hallmark of AD.
Current care may be improved using high performing blood biomarkers
to potentially shorten the diagnostic journey and facilitate the
early treatment of Alzheimer’s Disease.
Upon completion of this
activity, participants will be able to:
-
Understand the value of early diagnosis in the care management
of patients with cognitive impairment
-
Recognize the usual clinical care pathway for the evaluation of
patients with cognitive impairment and new expert
recommendations and appropriate use criteria on care management
-
Analyze the differences between different biomarker tests for
brain amyloid and their approaches for helping clinicians
diagnose Alzheimer’s disease
-
Evaluate the opportunity for a high-accuracy blood biomarker
test to streamline diagnosis and management strategies
Faculty:
Ian N. Kremer, JD, Executive Director, LEAD (Leaders Engaged on
Alzheimer's Disease) Coalition
Suzanne E. Schindler, MD, PhD, Associate Professor of Neurology,
Washington University School of Medicine
Joel B. Braunstein, MD, MBA, CEO and Co-Founder, C2N Diagnostics,
LLC
Gary Owens, MD, Moderator
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance,
independence, objectivity, and scientific rigor in all of their
activities.
Click Here To Continue |